ARTICLE | Finance
LSP to deploy $600M fund to retain larger stakes in early-stage European biotechs
New fund to target €25-€30M per company, with focus on European therapeutics and med-tech companies
March 10, 2020 10:57 PM UTC
LSP has formally closed its sixth fund at $600 million, the largest ever for a European life sciences fund. The firm joins a growing number of European VCs that have announced record fund-raisings in recent years, signaling increased funding opportunities for innovation coming out of European labs.
Last year LSP had a first close of the fund at €465 million ($519 million), already surpassing its final target of $450 million. The firm said it has a total of $1.1 billion to invest across LSP 6, LSP's Health Economics fund and its public fund. ...